Tainan, Taiwan

Inze Lin


 

Average Co-Inventor Count = 2.7

ph-index = 1


Location History:

  • Shan-Hua, TW (2013)
  • Tainan, TW (2022)

Company Filing History:


Years Active: 2013-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inze Lin: Innovator in Pharmaceutical Chemistry

Introduction

Inze Lin is a notable inventor based in Tainan, Taiwan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of crystalline forms of important compounds. With a total of 2 patents, Lin's work has the potential to impact the pharmaceutical industry positively.

Latest Patents

Lin's latest patents include a crystalline form of ivacaftor and a process for preparing the same. This invention provides crystalline forms of ivacaftor N-(2,4-di-tert-butyl-phenyl-5-hydroxy-phenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. The process involves forming a solution with crude ivacaftor and a solvent, adding an anti-solvent to create a slurry with a precipitate, isolating the precipitate, and drying it to yield crystalline forms S2, S3, S4, or S5 of ivacaftor. Additionally, he has developed solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and methods for making these forms.

Career Highlights

Inze Lin is currently associated with Scinopharm Taiwan, Ltd., where he continues to innovate in the field of drug development. His work is characterized by a focus on creating new forms of existing compounds, which can enhance their efficacy and stability.

Collaborations

Lin collaborates with talented coworkers, including Kuan-Hsun Huang and Li-Ting Wang, who contribute to his research and development efforts.

Conclusion

Inze Lin's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to advancing drug development. His work not only showcases his expertise but also highlights the importance of collaboration in scientific research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…